Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)

What is the purpose of this trial?

Visit the Alzheimer's Disease Research Unit (ADRU) here.

The purpose of this study is to assess the safety, tolerability and biomarker efficacy of Gantenerumab and Solanezumab in individuals who have an autosomal dominant Alzheimer's disease (ADAD) mutation.


Participation Guidelines

Ages: 18 - 80 years

Gender: Both


Washington University School of Medicine

Dates: 03/11/2014 - 09/30/2019

Last Updated: 11/17/2015

Study HIC#: 1308012526

Get Involved

For more information about this study, contact:
Carol Gunnoud
+1 203-764-8100
carol.gunnoud@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Christopher H Van Dyck

Principal Investigator

Sub-Investigators